Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)

被引：0
|
作者：
van Lokven, T.
Kempcke, R.
Ziemssen, T.
Meergans, M.
机构：
[1] Novartis Pharma GmbH, Nurnberg, Germany
[2] Karl Gustav Carus Univ Hosp, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P502
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [1] Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    van Lokven, T.
    Kempcke, R.
    Meergans, M.
    JOURNAL OF NEUROLOGY, 2012, 259 : S72 - S72
  • [2] Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
    Ziemssen, Tjalf
    van Lokven, Tom
    Kempke, Raimar
    Meergans, Matthias
    NEUROLOGY, 2012, 78
  • [3] Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Meergans, M.
    Vollmar, P.
    Kempcke, R.
    Tracik, F.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 222 - 223
  • [4] 18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
    Ziemssen, Tjalf
    Lorente, Maria Diaz
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Kempcke, Raimar
    van Lokven, Tom
    NEUROLOGY, 2013, 80
  • [5] 18-month interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Vollmar, P.
    Diaz-Lorente, M.
    Fuchs, A.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 318 - 318
  • [6] The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2015, 15
  • [7] The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 15
  • [8] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 16
  • [9] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2016, 16
  • [10] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
    Ziemssen, Tjalf
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Lorente, Maria Diaz
    Neidhardt, Katja
    van Lokven, Tom
    NEUROLOGY, 2013, 80
12345